BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25842974)

  • 1. New Japanese initiatives on stem cell therapies.
    Konomi K; Tobita M; Kimura K; Sato D
    Cell Stem Cell; 2015 Apr; 16(4):350-2. PubMed ID: 25842974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rejuvenating Regenerative Medicine Regulation.
    Charo RA; Sipp D
    N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
    [No Abstract]   [Full Text] [Related]  

  • 3. On the Road (to a Cure?)--Stem-Cell Tourism and Lessons for Gene Editing.
    Charo RA
    N Engl J Med; 2016 Mar; 374(10):901-3. PubMed ID: 26863030
    [No Abstract]   [Full Text] [Related]  

  • 4. Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.
    Takashima K; Morrison M; Minari J
    Stem Cell Reports; 2021 Jun; 16(6):1425-1434. PubMed ID: 34019814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional approval: Japan lowers the bar for regenerative medicine products.
    Sipp D
    Cell Stem Cell; 2015 Apr; 16(4):353-6. PubMed ID: 25842975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Social Framework Surrounding the Development of Regenerative Medicine in Japan.
    Nakazawa E; Takimoto Y; Akabayashi A
    Camb Q Healthc Ethics; 2016 Jul; 25(3):466-71. PubMed ID: 27348830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we assure quality without stifling innovation?
    Miller L
    Stem Cells Dev; 2014 Dec; 23 Suppl 1(Suppl 1):66-7. PubMed ID: 25457966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Japanese Laws and the Current Status of Regenerative Medicine in the Tohoku Region.
    Kamano Y; Terajima N; Chiba Y; Suresh VV; Saito M
    J Contemp Dent Pract; 2023 Feb; 24(2):120-128. PubMed ID: 37272144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A RAT by Another Name: 21
    Riley MF
    Am J Law Med; 2018 May; 44(2-3):291-308. PubMed ID: 30106653
    [No Abstract]   [Full Text] [Related]  

  • 11. Regenerative medicine legislation in Japan for fast provision of cell therapy products.
    Fujita Y; Kawamoto A
    Clin Pharmacol Ther; 2016 Jan; 99(1):26-9. PubMed ID: 26482927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
    Knoepfler PS
    Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell research and regenerative medicine in 2014: first year of regenerative medicine in Japan.
    Okano H
    Stem Cells Dev; 2014 Sep; 23(18):2127-8. PubMed ID: 25192239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allowing innovative stem cell-based therapies outside of clinical trials: ethical and policy challenges.
    Hyun I
    J Law Med Ethics; 2010; 38(2):277-85. PubMed ID: 20579251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Regulation of adoptive immunotherapy].
    Nakazawa Y; Suzuki S; Nishio N
    Rinsho Ketsueki; 2016; 57(11):2373-2380. PubMed ID: 27941288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Foreword: A compendium on latest developments in stem cell research and cell therapy applications.
    Koka PS; Khanna A
    J Stem Cells; 2009; 4(2):81-3. PubMed ID: 20232593
    [No Abstract]   [Full Text] [Related]  

  • 17. Global bionetworks and challenges in regulating autologous adult stem cells.
    Lysaght T; Kerridge I; Sipp D; Porter G; Capps BJ
    Am J Med; 2013 Nov; 126(11):941-3. PubMed ID: 24157285
    [No Abstract]   [Full Text] [Related]  

  • 18. Developing Induced Pluripotent Stem Cell-Based Therapy for the Masses.
    Rao MS; Atala A
    Stem Cells Transl Med; 2016 Feb; 5(2):129-31. PubMed ID: 26718646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balancing Safety and Innovation for Cell-Based Regenerative Medicine.
    Marks P; Gottlieb S
    N Engl J Med; 2018 Mar; 378(10):954-959. PubMed ID: 29514023
    [No Abstract]   [Full Text] [Related]  

  • 20. Accelerating Cell Therapy for Stroke in Japan: Regulatory Framework and Guidelines on Development of Cell-Based Products.
    Houkin K; Shichinohe H; Abe K; Arato T; Dezawa M; Honmou O; Horie N; Katayama Y; Kudo K; Kuroda S; Matsuyama T; Miyai I; Nagata I; Niizuma K; Sakushima K; Sasaki M; Sato N; Sawanobori K; Suda S; Taguchi A; Tominaga T; Yamamoto H; Yamashita T; Yoshimine T;
    Stroke; 2018 Apr; 49(4):e145-e152. PubMed ID: 29581346
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.